INC Research, Inc. Named Top 10 CRO in CenterWatch Inc. Global Survey

Published: May 02, 2011

RALEIGH, NC--(Marketwire - May 02, 2011) -

Highlighted Links

INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, today announced it has been rated one of the world's top CROs in the 2011 CenterWatch Global Investigative Site Survey. The company earned a number nine ranking among CROs in CenterWatch's first ever global survey, which included input from clinical research professionals at investigative sites across 74 countries.

"To be identified as one of the top 10 rated CROs globally is truly an honor and a reflection of the hard work and dedication from our high-performing teams worldwide," said James Ogle, CEO, INC Research. "Through our proven Trusted Process methodology, which we apply and maintain through our locally based teams, and our extensive therapeutic expertise, we're able to deliver a high level of investigative site support and reliable deliverables to clinical trial sponsors globally."

CenterWatch, a leading publishing and information services company focused on the clinical trials industry, conducted the survey, which included 1,205 respondents from 74 countries, in February and March 2011. Principal investigators comprised 65 percent of respondents while 13 percent were sub-investigators, and the remaining responses were from study coordinators and nurses. Of the 29 relationship attributes ranked, INC Research scored highest for its professional medical staff and its knowledgeable and professional monitors and CRAs. It also received high marks for maintaining open communication, effectively working with sponsors and holding informative investigator meetings.

"CenterWatch has been tracking and evaluating the quality of sponsor, CRO and investigative site relationships for the U.S., European, Asia-Pacific and Latin American markets since 1997, so expanding our survey globally was a logical extension, especially considering how clinical research has evolved into such a global enterprise," said Joan A. Chambers, COO for CenterWatch. "We received our best response rate ever with more than 1,200 sites worldwide responding. This shows how effective interactions between sponsors, CROs and their investigative sites have always been an important factor in the conduct of successful clinical trials and, ultimately, achieving accelerated clinical development cycle times. By being identified and rated as a top CRO worldwide, INC Research has clearly been able to extend its high-quality reputation on a global scale."

INC Research is a privately held, therapeutically focused global CRO with deep expertise in managing global Phase I through Phase IV clinical development programs. INC Research employs more than 2,000 people in 40 countries worldwide. The full-service CRO was recently ranked 10th on the list of Preferred CROs, an annual survey conducted by William Blair and was number 10 on the Scrip Clinical Research 25 list based on 2009 revenues.

About INC Research, LLC.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.